{"id":40549,"date":"2025-09-02T13:40:36","date_gmt":"2025-09-02T05:40:36","guid":{"rendered":"https:\/\/flcube.com\/?p=40549"},"modified":"2025-09-02T13:40:37","modified_gmt":"2025-09-02T05:40:37","slug":"santen-launches-tapcom-preservative%e2%80%91free-glaucoma-combo-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40549","title":{"rendered":"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China"},"content":{"rendered":"\n<p>Japan\u2011based <strong>Santen Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4536:TYO\">TYO: 4536<\/a>) announced the commercial launch of <strong>Tapcom<\/strong> (tafluprost\/timolol\u202fmaleate) in China, marking the first prescription ophthalmic combination in the country that contains a first\u2011line prostaglandin analog without preservatives.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Approval<\/strong> \u2013 The National Medical Products Administration granted approval in March\u202f2025 for Tapcom to lower intra\u2011ocular pressure (IOP) in patients with open\u2011angle glaucoma or ocular hypertension who exhibit inadequate response to monotherapy (beta\u2011blocker or prostaglandin analog) or who require preservative\u2011free therapy.<\/li>\n\n\n\n<li><strong>First\u2011In\u2011Class<\/strong> \u2013 Tapcom is the inaugural preservative\u2011free combination available in China, meeting a critical unmet need for chronic glaucoma patients.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile\">Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Active Ingredients<\/strong><\/td><td>Tafluprost (PG analog) + Timolol Maleate (beta\u2011blocker)<\/td><\/tr><tr><td><strong>Dosage Form<\/strong><\/td><td>Eye drop, once daily<\/td><\/tr><tr><td><strong>Preservative\u2011Free<\/strong><\/td><td>Eliminates benzalkonium chloride and other common preservatives<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Open\u2011angle glaucoma, ocular hypertension requiring combination therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-impact\">Clinical Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy &amp; Safety<\/strong> \u2013 Clinical data demonstrate that Tapcom achieves IOP\u2011lowering efficacy comparable to using two separate drops, with a safety profile consistent with its individual components.<\/li>\n\n\n\n<li><strong>Patient Convenience<\/strong> \u2013 Once\u2011daily dosing and the elimination of a second drop reduce treatment burden, improving adherence and overall quality of life.<\/li>\n\n\n\n<li><strong>Long\u2011Term Benefits<\/strong> \u2013 Reducing preservative exposure mitigates ocular surface disease and preserves corneal health in patients on lifelong therapy.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook\">Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Growing Demand<\/strong> \u2013 China\u2019s aging population and rising prevalence of glaucoma create a sizable addressable market for preservative\u2011free combination therapies.<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong> \u2013 Tapcom\u2019s unique positioning as the first preservative\u2011free PG analog\/beta\u2011blocker combo differentiates it from existing monotherapies and multi\u2011drop regimens.<\/li>\n\n\n\n<li><strong>Strategic Expansion<\/strong> \u2013 Santen plans to leverage its global distribution network to scale Tapcom across key Chinese regions, targeting both ophthalmology clinics and specialty pharmacies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Japan\u2011based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced the commercial launch of Tapcom (tafluprost\/timolol\u202fmaleate) in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40550,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[40,44,15,415,2079],"class_list":["post-40549","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-launch","tag-ophthalmology","tag-product-approvals","tag-santen-pharmaceutical","tag-tyo-4536"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan\u2019s Santen Pharmaceutical has rolled out its first preservative\u2011free ophthalmic combination, Tapcom (tafluprost\/timolol maleate), in China. The once\u2011daily PG analog\/beta\u2011blocker blend was approved by the NMPA in March\u202f2025 for patients with open\u2011angle glaucoma or ocular hypertension who need combination therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40549\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China\" \/>\n<meta property=\"og:description\" content=\"Japan\u2019s Santen Pharmaceutical has rolled out its first preservative\u2011free ophthalmic combination, Tapcom (tafluprost\/timolol maleate), in China. The once\u2011daily PG analog\/beta\u2011blocker blend was approved by the NMPA in March\u202f2025 for patients with open\u2011angle glaucoma or ocular hypertension who need combination therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40549\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-02T05:40:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-02T05:40:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0204.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China\",\"datePublished\":\"2025-09-02T05:40:36+00:00\",\"dateModified\":\"2025-09-02T05:40:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549\"},\"wordCount\":297,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0204.webp\",\"keywords\":[\"Market launch\",\"Ophthalmology\",\"Product approvals\",\"Santen Pharmaceutical\",\"TYO: 4536\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40549#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40549\",\"name\":\"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0204.webp\",\"datePublished\":\"2025-09-02T05:40:36+00:00\",\"dateModified\":\"2025-09-02T05:40:37+00:00\",\"description\":\"Japan\u2019s Santen Pharmaceutical has rolled out its first preservative\u2011free ophthalmic combination, Tapcom (tafluprost\\\/timolol maleate), in China. The once\u2011daily PG analog\\\/beta\u2011blocker blend was approved by the NMPA in March\u202f2025 for patients with open\u2011angle glaucoma or ocular hypertension who need combination therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40549\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0204.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0204.webp\",\"width\":1080,\"height\":608,\"caption\":\"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40549#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China - Insight, China&#039;s Pharmaceutical Industry","description":"Japan\u2019s Santen Pharmaceutical has rolled out its first preservative\u2011free ophthalmic combination, Tapcom (tafluprost\/timolol maleate), in China. The once\u2011daily PG analog\/beta\u2011blocker blend was approved by the NMPA in March\u202f2025 for patients with open\u2011angle glaucoma or ocular hypertension who need combination therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40549","og_locale":"en_US","og_type":"article","og_title":"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China","og_description":"Japan\u2019s Santen Pharmaceutical has rolled out its first preservative\u2011free ophthalmic combination, Tapcom (tafluprost\/timolol maleate), in China. The once\u2011daily PG analog\/beta\u2011blocker blend was approved by the NMPA in March\u202f2025 for patients with open\u2011angle glaucoma or ocular hypertension who need combination therapy.","og_url":"https:\/\/flcube.com\/?p=40549","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-02T05:40:36+00:00","article_modified_time":"2025-09-02T05:40:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0204.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40549#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40549"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China","datePublished":"2025-09-02T05:40:36+00:00","dateModified":"2025-09-02T05:40:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40549"},"wordCount":297,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40549#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0204.webp","keywords":["Market launch","Ophthalmology","Product approvals","Santen Pharmaceutical","TYO: 4536"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40549#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40549","url":"https:\/\/flcube.com\/?p=40549","name":"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40549#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40549#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0204.webp","datePublished":"2025-09-02T05:40:36+00:00","dateModified":"2025-09-02T05:40:37+00:00","description":"Japan\u2019s Santen Pharmaceutical has rolled out its first preservative\u2011free ophthalmic combination, Tapcom (tafluprost\/timolol maleate), in China. The once\u2011daily PG analog\/beta\u2011blocker blend was approved by the NMPA in March\u202f2025 for patients with open\u2011angle glaucoma or ocular hypertension who need combination therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40549#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40549"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40549#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0204.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0204.webp","width":1080,"height":608,"caption":"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40549#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Santen Launches Tapcom, Preservative\u2011Free Glaucoma Combo in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0204.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40549"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40549\/revisions"}],"predecessor-version":[{"id":40551,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40549\/revisions\/40551"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40550"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}